GlassScriptPhysician profile
Cathia M Rene
NPI 1306928924
$7,984.14
in general payments reported to CMS, 2019-2025
34 companies · $1,422 in 2025
The $1,422 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $732 · 2020: $342 · 2021: $694 · 2022: $1,397 · 2023: $1,188 · 2024: $2,210 · 2025: $1,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,944 · Travel and Lodging: $700 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,944.24 |
| Travel and Lodging | $700.11 |
| Education | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,192.78 | 2022-2025 | Interstim, Pillcam |
| Abbvie INC. | $1,739.34 | 2019-2025 | |
| Janssen Biotech, INC. | $1,316.98 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $484.00 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $305.47 | 2019-2025 | Eohilia, Entyvio, Gattex |
| Pfizer INC. | $292.68 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $186.58 | 2024-2025 | Voquezna |
| Celgene Corporation | $162.01 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $138.75 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $102.48 | 2024-2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $95.13 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $79.97 | 2023-2025 | Rebyota, Clenpiq |
| Genzyme Corporation | $74.30 | 2023 | |
| Lilly USA, LLC | $73.31 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $69.67 | 2024-2025 | Zenpep, Vowst |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $68.73 | 2019-2023 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.21 | 2019-2024 | Trulance |
| Redhill Biopharma INC. | $66.69 | 2022-2023 | Talicia |
| Ucb, INC. | $51.97 | 2019 | |
| Biocon Biologics INC | $49.65 | 2025 | Yesintek |
| Axonics, INC. | $48.12 | 2023 | Axonics |
| Micro-Tech Endoscopy USA, INC. | $47.06 | 2022-2024 | Dat Device, Cold Snares |
| Qol Medical, LLC | $44.88 | 2023 | Sucraid |
| Merck Sharp & Dohme LLC | $36.70 | 2021-2022 | |
| Braintree Laboratories, INC. | $30.41 | 2019-2022 | |
| Allergan, INC. | $23.35 | 2019 | |
| Amgen INC. | $19.26 | 2023 | Avsola, Amjevita |
| Vivus LLC | $19.22 | 2022 | |
| Daiichi Sankyo INC. | $19.02 | 2020 | |
| Alfasigma USA, INC. | $17.71 | 2020 | |
| Evoke Pharma, INC. | $16.82 | 2023 | Gimoti |
| Nestle Healthcare Nutrition INC. | $15.25 | 2023 | |
| Shire North American Group INC | $14.13 | 2019 | |
| Madrigal Pharmaceuticals | $13.51 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathia Rene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.